Brief: Sirnaomics Dosed First Patient In Phase I Clinical Study Of Galnac-Based Rnai Therapeutic Stp122g For Anticoagulant Treatment
01/06/2023 20:15
June 1 (Reuters) - Sirnaomics Ltd 2257.HK :
* SIRNAOMICS DOSED THE FIRST PATIENT IN PHASE I CLINICAL
STUDY OF
GALNAC-BASED RNAI THERAPEUTIC STP122G FOR ANTICOAGULANT
TREATMENT
Recent news on Sirnaomics
See all newsBrief: Sirnaomics Announces RMB30 Million Capital Injection For Deemed Disposal
Brief: Sirnaomics And Unit Files Writ Of Summons Against Former Management
Brief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares